Management of Prolonged Bleeding with Contraceptive Use

Initial Assessment and Treatment

The Centers for Disease Control and Prevention recommends ruling out underlying gynecological problems that could cause prolonged bleeding, including pregnancy, sexually transmitted infections, and pathologic uterine conditions, in a patient experiencing prolonged bleeding with Nexplanon implant and previous NuvaRing use 1
For a patient with prolonged bleeding, the American College of Obstetricians and Gynecologists suggests a short course of NSAIDs, such as mefenamic acid (500 mg three times daily for 5 days) or celecoxib (200 mg daily for 5 days), as a first-line treatment option 1, 2
Low-dose combined oral contraceptives for 10-20 days can be considered as an alternative treatment option for medically eligible patients with prolonged bleeding 1, 2

The Centers for Disease Control and Prevention reports that 18% of Nexplanon users experience prolonged bleeding, and 7% experience frequent bleeding, which are generally not harmful but can be bothersome 2
Mefenamic acid 500 mg three times daily for 5 days has been shown to significantly cease bleeding within 7 days, with a similar effect seen with celecoxib 200 mg daily for 5 days 2
The strength of evidence for these treatment options is based on moderate-quality studies, with a recommendation grade of B, indicating that the benefits of the treatment outweigh the harms 1, 2

If bleeding persists after initial treatment, the American College of Obstetricians and Gynecologists recommends counseling on alternative contraceptive methods and considering removing Nexplanon if bleeding severely impacts quality of life 1
For patients who wish to continue with Nexplanon despite irregular bleeding, the Centers for Disease Control and Prevention suggests providing reassurance that bleeding irregularities are generally not harmful and considering intermittent treatment with NSAIDs during episodes of bleeding 1
Enhanced counseling about expected bleeding patterns with Nexplanon can improve continuation rates, with a moderate level of evidence supporting this recommendation 2